TY - JOUR
T1 - A new measure to assess asthma's effect on quality of life from the patient's perspective
AU - Wilson, Sandra R.
AU - Mulligan, Michael J.
AU - Ayala, Estela
AU - Chausow, Alan
AU - Huang, Qiwen
AU - Knowles, Sarah B.
AU - Gummidipundi, Santosh
AU - Castro, Mario
AU - Wise, Robert A.
N1 - Funding Information:
Supported by grant no. HL119845 (principal investigator: S. R. Wilson) from the National Heart, Lung and, Blood Institute/National Institutes of Health.
Publisher Copyright:
© 2017 American Academy of Allergy, Asthma & Immunology
PY - 2018/3
Y1 - 2018/3
N2 - Background: The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses the negative effect of asthma on quality of life (QoL) from the patient's perspective by using dimensions of Flanagan's Quality of Life Scale (QOLS), a measure of current QoL. Objectives: We sought to determine and compare the psychometric properties of the A-IQOLS and QOLS, including their sensitivities to differences and change in asthma status. Methods: In a test-retest design (3- to 5-week interval) adults with persistent asthma underwent spirometry and were administered the A-IQOLS, other asthma outcome measures (Asthma Control Test, Asthma Symptom Utility Index, and the Marks and Juniper Asthma Quality of Life Questionnaires), and the QOLS. Results: Participants’ (n = 147) mean age was 49 years, 76% were white, 12% were Hispanic, and 65% were female. A-IQOLS and QOLS scores were significantly correlated with other asthma outcomes scores, except FEV 1 , but shared relatively low common variance with these measures. A-IQOLS but not QOLS score changes were significantly correlated with changes in asthma outcomes. An A-IQOLS standard error of measurement of 0.27 implies that a within-person score change of ±0.73 or greater constitutes a true change. The QOLS standard error of measurement was 0.43. Conclusions: A-IQOLS provides a reliable, valid, and unique assessment of the patient-perceived negative effect of asthma on QoL that is suitable for use in asthma clinical research and potentially in clinical care. Further studies are needed in diverse patient populations. QOLS, a measure of current QoL, is less sensitive to disease status changes but might be useful in characterizing study populations, in treatment adherence research, and as a clinical and research tool in patients with multiple, severe, and/or life-limiting chronic conditions.
AB - Background: The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses the negative effect of asthma on quality of life (QoL) from the patient's perspective by using dimensions of Flanagan's Quality of Life Scale (QOLS), a measure of current QoL. Objectives: We sought to determine and compare the psychometric properties of the A-IQOLS and QOLS, including their sensitivities to differences and change in asthma status. Methods: In a test-retest design (3- to 5-week interval) adults with persistent asthma underwent spirometry and were administered the A-IQOLS, other asthma outcome measures (Asthma Control Test, Asthma Symptom Utility Index, and the Marks and Juniper Asthma Quality of Life Questionnaires), and the QOLS. Results: Participants’ (n = 147) mean age was 49 years, 76% were white, 12% were Hispanic, and 65% were female. A-IQOLS and QOLS scores were significantly correlated with other asthma outcomes scores, except FEV 1 , but shared relatively low common variance with these measures. A-IQOLS but not QOLS score changes were significantly correlated with changes in asthma outcomes. An A-IQOLS standard error of measurement of 0.27 implies that a within-person score change of ±0.73 or greater constitutes a true change. The QOLS standard error of measurement was 0.43. Conclusions: A-IQOLS provides a reliable, valid, and unique assessment of the patient-perceived negative effect of asthma on QoL that is suitable for use in asthma clinical research and potentially in clinical care. Further studies are needed in diverse patient populations. QOLS, a measure of current QoL, is less sensitive to disease status changes but might be useful in characterizing study populations, in treatment adherence research, and as a clinical and research tool in patients with multiple, severe, and/or life-limiting chronic conditions.
KW - Asthma
KW - clinical outcomes
KW - measurement/standardized measures
KW - patient-centered outcomes
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85021276552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021276552&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2017.02.047
DO - 10.1016/j.jaci.2017.02.047
M3 - Article
C2 - 28579376
AN - SCOPUS:85021276552
SN - 0091-6749
VL - 141
SP - 1085
EP - 1095
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -